Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
friluglanstat
- Development stage
- Phase 1
- Lead developer
- Nippon Shinyaku
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NS-580 (friluglanstat) is an orally available small molecule inhibitor of microsomal prostaglandin E synthase-1 (mPGES-1), developed by Nippon Shinyaku. It is a new molecular entity under clinical development for the treatment of endometriosis, chronic pelvic pain, and chronic prostatitis/chronic pelvic pain syndrome. The drug acts by inhibiting mPGES-1, thereby reducing the synthesis of prostaglandin E2, which plays a role in inflammation and pain. Clinical trials have reached phase II for these indications in Japan and the United Kingdom[1][2][3][4][5].
- Other names
- NS 580NS580NS-580
02
Targets
PTGES (Microsomal prostaglandin E synthase-1)
Beyond the preview
Go deeper on friluglanstat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on friluglanstat.